#1COPYRIGHT © ABCELLERA CORPORATE OVERVIEW November 2023 AbCellera#2CORPORATE OVERVIEW COPYRIGHT © ABCELLERA 2 DISCLAIMER This presentation contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management's beliefs and assumptions and on information currently available to management. All statements contained in this presentation other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations. In some cases, you can identify forward-looking statements by the words "may,” “will,” “could,” “would," "should," “expect,” “intend," "plan," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue," "ongoing" or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this presentation represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.#3CORPORATE OVERVIEW COPYRIGHT © ABCELLERA 3 AbCellera is an antibody discovery engine that delivers optimal clinical candidates to the clinic - and to patients with greater precision and speed. HYPOTHESIS Investments in technology can improve the productivity of drug development. PHILOSOPHY Long-term value creation begins with building a great company that can create multiple products.#4CORPORATE OVERVIEW COPYRIGHT © ABCELLERA 4 DRUG DEVELOPMENT HAS THREE STEPS. Target Identification IDEATION Drug Discovery regulations, technology, science, manufacturing, lab space, talent PRODUCT CREATION 3 to 5 years 1000+ steps Clinical Development PRODUCT TESTING 7 to 10 years |#5CORPORATE OVERVIEW COPYRIGHT © ABCELLERA 5 TECHNOLOGY CAN MAKE A BIG IMPACT ON PRODUCT CREATION. Illustrative drug development investment profile: Years since program start Stage of program development I Technology intensive 1y 2y Discovery to IND 3y 4y 5y Phase 1 - 6y 7y Phase 2 - 8y 9y Phase 3 POS: >5% 10y 11y 12y 13y 14y 15y Commercial Sales 16y 17y Peak sales ~$1B 18y 19y 20y 21y#6CORPORATE OVERVIEW COPYRIGHT © ABCELLERA 6 со STRATEGY #1 Be best in world in antibody therapeutics from target to the clinic. STRATEGY #2 NO Build a large and diversified portfolio of stakes in future antibody therapeutics.#7CORPORATE OVERVIEW COPYRIGHT © ABCELLERA 7 STRATEGY #1 Be best in world in antibody therapeutics from target to the clinic. from TARGET TECHNOLOGY DATA SCIENCE THE ENGINE EXPERTS INFRASTRUCTURE INTEGRATION X to PATIENTS 2x faster solve the unsolvable highest quality unprecedented scale#8CORPORATE OVERVIEW COPYRIGHT © ABCELLERA 8 ● SPEED $100M+ NPV by accelerating approval of an average antibody drug by 1 year NEW MARKETS $100B+ new market opportunities unlocked by drugging the undruggable Billions sales, profit, value by being first to market LEVEL THE PLAYING FIELD $50M+ small biotech savings from not having to reinvent the wheel Best-in-world capabilities create value.#9CORPORATE OVERVIEW COPYRIGHT © ABCELLERA 9 STRATEGY #2 Build a large, diverse portfolio of stakes in future antibody therapies. PARTNER-INITIATED PROGRAMS Discovery Programs Co-Development Programs X TECHNOLOGY-DEVELOPMENT Pre-Partnered Programs#10CORPORATE OVERVIEW COPYRIGHT © ABCELLERA 10 PARTNER-INITIATED PROGRAMS Discovery Programs TARGET Partner-initiated DEAL TERMS Upfronts and research fees Clinical milestones Single-digit royalties on net sales ● ● High volume deals with highly diversified positions and high ROI.#11CORPORATE OVERVIEW COPYRIGHT © ABCELLERA 11 PARTNER-INITIATED PROGRAMS Co-Development Programs TARGET Partner-initiated DEAL TERMS Upfronts, clinical milestones, and royalty position PLUS option to co-invest in program development to maintain up to a 50% ownership position ● ● Low volume deals with optionality for concentrated positions.#12CORPORATE OVERVIEW COPYRIGHT © ABCELLERA 12 TECHNOLOGY-DEVELOPMENT Pre-Partnered Programs Untapped market opportunity in an area with a high technical barrier to entry and a rich target space that includes many targets. T-Cell Engagers Platform GPCRs & Ion Channels Platform Pandemic Response Platform High-value, well-validated targets that have been intractable using fragmented approaches and traditional technology. Tech-intensive challenge requiring complex integration to deliver antibody therapies quickly and bring new treatments to address emerging variants. Technology development efforts with potential to generate first-in-class wholly-owned assets.#13CORPORATE OVERVIEW COPYRIGHT © ABCELLERA 13 PRE-PARTNERED PROGRAMS: T-CELL ENGAGERS BRING BEST-IN-CLASS T-CELL ENGAGERS TO THE CLINIC, FASTER strike the right balance We have developed hundreds of CD3-binding antibodies that are differentiated from commonly used molecules. ●........... build bispecifics We precisely pair parental antibodies with our clinically validated bispecific engineering platform, OrthoMab™ hit tumor targets We streamline discovery of highly specific and developable tumor-binding antibodies for diverse tumor targets. find the right match We identify the optimal pair with high-throughput functional and biophysical assays.#14CORPORATE OVERVIEW COPYRIGHT © ABCELLERA 14 PORTFOLIO DIVERSIFIED ACROSS MODALITIES, PARTNER SIZE, AND DEAL TYPE. 69** 6* partner-initiated partner-initiated discovery program starts** co-development program starts** 41 partners 9 molecules in the clinic * As of December 31, 2022 ** With downstream participation 12* pre-partnered program starts (TCE, GPCR, ion channel, Covid-19) 2 authorized antibody therapies REGENERON gsk NOVARTIS GILEAD Ablynx A SANOFI COMPANY EMPIRICO ANART SANHIARSH THE AUTRES LLOW ANY Autolus TACHYON Lilly له EVEREST MEDICINES SANOFI biosciences Rallybio angios Lyell teva moderna EQR™ REMAKING MEDICINE Pfizer KODIAK DENALI X Invetx MERCK BILL & MELINDA GATES foundation#15CORPORATE OVERVIEW COPYRIGHT © ABCELLERA 15 ONE DECADE OF ENGINE BUILDING. investments ~525 employees across 4 countries and 3 continents 650K+ sq.ft. of facilities lab, office, & manufacturing spaces by 2024 $500M+ platform investments capitalization $800M+ in equity raised since 2012 sheet $150M+ in government contracts and financing 30% + held by employees & directors financials $800M+ in total cash, cash equivalents & marketable securities ble TA $350M+ in accumulated earnings since 2012 KIMTECH#16STRATEGIC FUNDING UPDATE COPYRIGHT © ABCELLERA AbCellera secures $222M (CA$300M) non-dilutive funding to accelerate execution of strategy and bring pre-partnered programs into clinic Government co-investment is non-dilutive and provides certainty for accelerated strategy execution with high capital efficiency ● ● Total $519 million (CA$701 million) co- investment, AbCellera contribution $296 million (CA$401 million) Government contribution is mix of 20% grant, 55% success-contingent repayable, and 25% unconditionally repayable funds (unsecured debt) Funding drawn as investments are made, extending existing long cash runway FUNDING SOURCES $296M AbCellera $519M $167M Strategic Innovation Fund (Federal) $56M BC Investments will further strengthen leading engine to discover and develop antibody therapies, from target to patients - and do so in Canada Accelerate build-out of fully- integrated capabilities from target into Phase 1 trials Quickly leverage and demonstrate late-stage pre-clinical capability investments with pre-partnered programs Generate experience in and beneficial learnings from taking programs into the clinic PROJECT INVESTMENTS $224M Lab & Office Construction stronger engine $193M Drug Candidate R&D $519M $102M Clinical Studies enhanced portfolio Funding additional pre- partnered programs will enhance size and value of portfolio of stakes in future antibody therapies in multiple ways ● Initiate up to 17 programs with initial focus on cancer and immune disease Advance multiple programs through Phase 1, yielding clinical assets for partnering Strengthen program economics by visibly adding value from target into clinic As a result, AbCellera will be an even stronger company, propelling antibody-based medicines from target to clinic with precision and speed ● ● ● May 24th, 2023 ● Fully integrated target-to- patient capabilities at scale will be fully in place Track record of taking programs through Phase 1 will be robustly established Portfolio will be expanded with deep economic stakes in advanced programs Already substantial liquidity runway will be significantly extended#17PIPELINE UPDATE COPYRIGHT © ABCELLERA 17 PROGRAMS Two AbCellera-led programs advancing into IND-enabling studies. MOLECULE ABCL575 ABCL635 TARGET OX40L undisclosed GPCR or ion channel INDICATION atopic dermatitis undisclosed THERAPEUTIC AREA immunology and inflammation metabolic and endocrine conditions POTENTIAL DIFFERENTIATION best in class first in class November 2nd, 2023 POTENTIAL MARKET SIZE $17B by 2032* >$2B * Source: IQVIA#18CORPORATE OVERVIEW COPYRIGHT © ABCELLERA 18 2 TECHNOLOGY 3 & COMPANY BUILDING H|M PARTNERING PARTNERED PROGRAMS Deal quality, not volume Deeper partnerships that get partners to the clinic Execute on and expand existing partnerships PRE-PARTNERED PROGRAMS GPCRs and ion channels T-cell engagers Pandemic response (COVID-19) ● ● ● PEOPLE & PLATFORM Team development Data science ● ● ● Translational science Manufacturing AbCellera's capital allocation#19CORPORATE OVERVIEW COPYRIGHT © ABCELLERA 19 IT'S BECAUSE IT'S HARD THAT IT'S VALUABLE & IT'S DEFENSIBLE. AbCellera's competitive moat CAPITAL TECHNOLOGY DATA SCIENCE THE ENGINE SCALE EXPERTS INFRASTRUCTURE INTEGRATION TIME#20CORPORATE OVERVIEW COPYRIGHT © ABCELLERA 20 This is what's needed to solve the problem. FROM TARGET TO DRUG Abr#2121 COPYRIGHT © ABCELLERA CORPORATE OVERVIEW THANK YOU